ArticlePeerJ2026
Multi-omics analysis reveals key genes associated with clear cell renal cell carcinoma.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most common type of kidney cancer is ccRCC (Clear Cell Renal Cell Carcinoma). Existing research has shown that when kidney cancer progresses from T2 to T3 or T4 stage, the treatment options and prognosis significantly differ. The aim of this study is to identify prognosis-related genes in ccRCC using single-cell data and Mendelian randomization analysis. Methods: Single-cell RNA sequencing (scRNA-seq) data from six ccRCC patients (GSE156632) were analyzed in R. After quality control and normalization, cells were embedded, clustered, and annotated to define major cell types. Cell-cell signaling networks were inferred using CellChat. Stage-related co-expression programs were identified using high-dimensional weighted gene co-expression network analysis (hdWGCNA), and modules enriched in advanced disease were prioritized. To connect expression patterns with germline variation, we obtained expression quantitative trait loci (eQTL) summary statistics from the UK Biobank and performed two-sample Mendelian randomization using the ukb-b-1316 exposure dataset. For clinical validation, bulk RNA-seq and survival data from The Cancer Genome Atlas (TCGA) were incorporated, and candidate genes were evaluated using univariable Cox proportional hazards models. Results: hdWGCNA identified three modules, from which we selected 150 genes. eQTL combined with Mendelian randomization analysis revealed a potential causal relationship between RBP5, PRDX2, GTSF1, BSG, and COX14 and tumorigenesis. Further TCGA data analysis indicated that PRDX2 might serve as a protective factor in ccRCC, consistent with the Mendelian randomization results. Furthermore, its expression exhibited a gradual decline with tumor stage progression. Kaplan-Meier(KM) curves demonstrated better prognosis for patients with high PRDX2 expression. Cell communication analysis revealed more frequent communication between cells with reduced PRDX2 expression and vascular endothelial cells. Moreover, the experiments demonstrate that the migration and proliferation abilities of ccRCC cells are enhanced after knocking down PRDX2. Conclusion: These results suggest that PRDX2 may play a role in the progression of ccRCC and could potentially serve as a prognostic factor and therapeutic target for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.